| |
 |
|
In February 2009, we sold the U.S. rights of Vitaros®, our Phase III product for Erectile Dysfunction, to Warner Chilcott Company, Inc. |
|
|
|
 |
|
In March 2010, we acquired PrevOnco®, a marketed anti-ulcer compound, lansoprazole, for the treatment of solid tumors from FasTrack Pharmaceuticals. The product is presently in Phase II development and may be cleared in mid 2010 to enter directly into Phase III testing as a second line therapy for the treatment of human hepatocellular carcinoma |
|
